March 2023
1. TANNE JH
   Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
   BMJ. 2023;380:p628.
   

   >> Share

   
   January 2023
2. MAHASE E
   Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.
   BMJ. 2023;380:p73.
   

   >> Share

   
   
3. TANNE JH
   Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report.
   BMJ. 2023;380:p6.
   

   >> Share

   
   December 2022
4. WALSH S, Merrick R, Richard E, Nurock S, et al
   Lecanemab for Alzheimer's disease.
   BMJ. 2022;379:o3010.
   

   >> Share

   
   August 2022
5. DYER O
   Alzheimer's: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease.
   BMJ. 2022;378:o2041.
   

   >> Share

   
   April 2022
6. DHANA K, Franco OH, Ritz EM, Ford CN, et al
   Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
   BMJ. 2022;377:e068390.
   

   >> Share

   
   March 2022
7. DYER O
   Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
   BMJ. 2022;376:o808.
   

   >> Share

   
   January 2022
8. LYTHGOE MP, Jenei K, Prasad V
   Regulatory decisions diverge over aducanumab for Alzheimer's disease.
   BMJ. 2022;376:e069780.
   

   >> Share

   
   December 2021
9. MAHASE E
   Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
   BMJ. 2021;375:n3127.
   

   >> Share

   
   November 2021
10. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    

    >> Share

    
    September 2021
11. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    

    >> Share

    
    August 2021
12. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    

    >> Share

    
    July 2021
13. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    

    >> Share

    
    
14. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    

    >> Share

    
    June 2021
15. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    

    >> Share

    
    
16. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    

    >> Share

    
    February 2021
17. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    

    >> Share

    
    October 2020
18. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share